/Companies

Modulus Therapeutics

acquired by Ginkgo Bioworks

Seattle, US · Founded 2020 · Delaware corporation · 3 known investors

Find your way into Modulus Therapeutics

Sign up to see every warm intro you have to Modulus Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Modulus Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Ginkgo Bioworks April 2024 · terms undisclosed · source ↗

Modulus Therapeutics applies in-house gene editing, in vivo screening, multi-omics, and machine learning in an iterative design process to develop optimized cell therapeutics. The company aims to make its cell-therapy design approach scalable and repeatable across diseases and cell types.

Founders & leadership

BR
Bryce R DainesNamed on SEC filing
MC
Max C DarnellNamed on SEC filing
MD
Max DarnellCo-Founder & CEO
BD
Bryce DainesCo-Founder & CTO
MY
Mary YoungHead of Biology
BB
Brian BelmontHead of Discovery Platform
LG
Lan GuoHead of Data Science

Investors · 3

KdT Ventureslisted by KdT VenturesAustin · $500K – $3M

How we know: KdT Ventures's portfolio page · a partner's Signal profile · funding news · press coverage · the VCSheet dataset · Not right? Tell us

Also in the syndicate · 1

Allen Institute for AI (AI2)

Reported raises · per SEC filings

Form D private placements

$3.8M disclosed across 1 round · 2021

▶$3.8MraisedJul 2021 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bryce R DainesExecutive Officer, Director
  • Max C DarnellExecutive Officer, Director
Offering amount
$3.8M
Amount sold
$3.8M
Minimum investment
$125K
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Modulus Therapeutics do?
Modulus Therapeutics applies in-house gene editing, in vivo screening, multi-omics, and machine learning in an iterative design process to develop optimized cell therapeutics. The company aims to make its cell-therapy design approach scalable and repeatable across diseases and cell types.
Who are Modulus Therapeutics's investors?
Modulus Therapeutics's investors include KdT Ventures, Madrona Venture Group.
How much funding has Modulus Therapeutics raised?
Modulus Therapeutics has disclosed $3.8M raised across 1 round.
Who acquired Modulus Therapeutics?
Modulus Therapeutics was acquired by Ginkgo Bioworks.
Where is Modulus Therapeutics headquartered?
Modulus Therapeutics is headquartered in Seattle, US.